Translate
Translate this website into the following languages:



Close Tab
Donations
UC San Diego Health
menu iconMenu
search iconSearch

UC San Diego Moores Cancer Center Offers New Hope for Deadly Brain Tumor

 

February 03, 2012  |  

One of few clinical trial sites, worldwide

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM).  In the United States, each year, approximately 10,000 patients are affected by GBM.  Now, a novel investigational device – available only at clinical trial sites – is offering new hope to these patients.

The non-invasive procedure – called Tumor Treating Fields (TTF) – is delivered using a portable device – called the NovoTTF-100A System made by Novocure.  The TTF procedure uses alternating electrical fields to disrupt the rapid cell division exhibited by cancer cells. 
 

 Santosh Kesari
Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center.
“Patients with recurrent GBM present a significant treatment challenge,” said Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center.  “The initial clinical research for the approval trial demonstrated that, compared to patients who were treated with chemotherapy, patients treated with NovoTTF achieved comparable survival times, had fewer side effects, and reported improved quality of life.”

 

On average, a patient with GBM survives less than 15 months with optimal treatment and only three to five months without additional effective treatment.  The TTF procedure may provide physicians with a fourth treatment option in addition to surgery, radiation therapy and chemotherapy.

TTFs inhibit tumor growth by causing cancerous cells to die.  The TTF procedure is delivered using non-invasive, insulated transducer arrays (electrodes) that are placed directly on the skin in the region of the tumor.  The hat-like collection of electrodes connects to a portable device which is slightly thicker than a laptop and weighs about six pounds.  The device sends a low intensity, alternating electric field into the tumor which prevents the cells from dividing and spreading and causes cancer cells to die. 

The most commonly reported side effect from NovoTTF is a mild-to-moderate scalp rash, beneath the electrodes.  The FDA-approved device is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

“When all other options have been exhausted, patients are willing to do just about anything to keep the tumor at bay,” said Kesari.  “This device gives them an opportunity to fight back, to feel like they are taking an active, hands-on role in their own treatment, and provides tremendous hope.”

# # #

Media Contact: Kim Edwards, 619-543-6163, kedwards@ucsd.edu


Related Specialties



Media Contact

Share This Article


Related News

7/27/2016
Ahead of the Summer Olympic Games in London four years ago, researchers reported that physical inactivity was a global pandemic that required urgent action. With the 2016 Games looming, University of ...
7/27/2016
The number of women living to age 90 in the United States has increased significantly in the past century. Currently estimated at 1.3 million, this demographic is expected to quadruple by 2050. A new ...
7/21/2016
In recognition of the Institutional Research and Academic Career Development Award (IRACDA) program at the University of California San Diego, which provides mentored training to postdocs in biomedica ...
7/21/2016
In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moore ...



Follow Us

Our bimonthly newsletter delivers healthy lifestyle tips, patient stories and research discovery news. Subscribe: